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Abstract
Background: Recent studies have suggested a strong link between migraines and restless legs syndrome (RLS). It is possible that these disorders share a
dopaminergic dysfunction in the hypothalamic A11 nucleus that contributes to this association. However, there have been no clinical studies to evaluate the effect of
dopaminergic treatment on migraine symptoms in patients with concomitant migraines and RLS.
Methods: We present an illustrative patient with concomitant RLS and migraine who showed improvement in her headache frequency and RLS symptoms
following immediate-release pramipexole (P-IR) treatment and provide review results from the medical records of patients who experienced both migraines and
RLS in our previous cross-sectional study.
Results: Ten patients (nine patients from the previously completed single-center study) received P-IR treatment were included in the study. RLS symptoms
improved markedly in all of the subjects. Five out of the 10 patients (50%) reported improvement in migraine headaches. Of these five patients, four (80%) had
reported morning headaches before P-IR treatment.
Discussion: Our results indicate that the identification of RLS in migraine patients is clinically significant and that dopaminergic treatment may improve both
migraines, particularly morning headache (80% improvement in this study), and RLS symptoms. However, further clinical studies are warranted to verify our
results.
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Introduction
A growing body of evidence suggests a strong link between
migraines and restless legs syndrome (RLS),1–4 which was recently
confirmed by a large prospective population-based study consisting of
31,370 women. This study demonstrated that women with migraines
with and without aura have an increased risk for developing RLS.5
Thus, the frequent comorbidity of migraine and RLS and its shared
clinical features, such as sleep disturbances and depression, indicate
that the two disorders have an overlapping pathophysiology, such as
dopaminergic dysfunction and dysfunctional brain iron metabolism.6
In addition, a positive family history was common in the two disorders.
In our previous study, approximately one-third of the subjects
diagnosed with RLS and migraine had a positive family history for
migraine and RLS.4 Central dopaminergic dysfunction in the
hypothalamic A11 area has been postulated in both migraines and
RLS,6,7 and it is likely to participate in the development or worsening
of both symptoms because the A11 dopaminergic nucleus inhibits
firing in the trigeminocervical complex,7 a key region for the
transmission of migraine information from the head and orofacial
structures to the hypothalamus and brain. Moreover, the A11 nucleus
also sends direct inhibitory projections to preganglionic sympathetic
neurons and the dorsal and anterior horns in the spinal cord,
innervating skeletal muscle. However, no clinical studies have been
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performed to evaluate the effect of chronic low-dose dopaminergic
treatment on migraine symptoms in patients with concomitant
migraines and RLS. We recently encountered a patient with
concomitant RLS and migraine who exhibited improvement in her
headache frequency and RLS symptoms following low-dose admin-
istration of immediate-release pramipexole (P-IR). This observation
led us to investigate whether P-IR improves not only clinical RLS
symptoms but also migraine headaches in patients with concomitant
migraines and RLS. Here, we present the illustrative case and provide
the review results of the medical records of patients who experienced
both migraines and RLS from our previous cross-sectional study.4
Methods
We investigated whether P-IR improved RLS and migraine
headache symptoms in patients who had both migraines and RLS
and received long-term P-IR treatment by reviewing the patients’
medical records and headache diaries. Most of the patients were
identified from a previously performed cross-sectional single-center
study on migraines and RLS.4 This study was conducted in the
outpatient headache clinic of the Department of Neurology at Dokkyo
Medical University. A referral is recommended but not necessary; in
fact, most of the patients who visited our headache outpatient clinic
were not referral cases. The migraines were diagnosed according to the
criteria from the International Classification of Headache Disorders
II,8 and RLS was diagnosed on the basis of four essential criteria, as
described by the International Restless Legs Syndrome Study Group.9
RLS was identified in 36 of 262 (13.7%) migraine patients and in three
of 163 healthy control subjects (1.8%). Of the 36 patients, 11 received
P-IR treatment. Of these 11 patients, two were lost to follow-up. In
addition, one newly diagnosed patient (the present case) with both
migraine and RLS was included. Thus, a total of 10 female patients
(mean age 35.3¡14.0 years) were included in the study. The patients’
background characteristics, including their Beck Depression
Inventory-II (BDI-II),10 International Restless Legs Syndrome Study
Group Rating Scale (IRLS),11 Pittsburgh Sleep Quality Index
(PSQI),12 and Epworth Sleepiness Scale (ESS),13 were obtained from
the patients’ clinical records. Migraine characteristics (pulsating,
tightening, or pressing), the onset age of RLS and migraine, changes
in migraine headache frequency before and after P-IR treatment, P-IR
daily dose, treatment duration, and concomitant medication in these
patients were carefully assessed by reviewing the medical record and
headache diary of each patient and by obtaining their comments from
the repeated interview. The IRLS includes 10 questions related to RLS
symptoms and their impacts on the patient’s mood and daily
functioning. The score ranges from 0 to 40 (1–10, mild; 11–20,
moderate; 21–30, severe; 31–40, very severe symptoms of RLS).11 All
of the patients included in this study were given P-IR for their RLS
symptoms and were not advised of the possible effect of P-IR on
migraine as the effect of P-IR on migraine was initially not expected.
None of the patients received any new treatment for migraine after the
P-IR treatment was started.
All participants were informed about the study design to investigate
the relationship between migraine and RLS and were informed that
they could receive adequate treatment for underlying diseases
including RLS during the study period, if identified. The study was
approved by the institutional review board, and written informed
consent was provided by all patients.
An illustrative case
A 35-year-old woman visited our outpatient clinic because of
insomnia due to abnormal sensation in the legs. Since childhood, she
had felt the urge to move her legs because of abnormal sensation,
which occurred during daytime at school (during class) and was
relieved by movement. She denied having either muscle cramp or
intermittent claudication. Since the age of 18 years, her restlessness
predominantly occurred in the late evening, causing difficulty falling
asleep and nocturnal awakening. The patient did not smoke, drink
alcohol, or take any regular medication apart from triptan for migraine
attack. The past medical history included depression at the age of 23
years and dyslipidemia. She has suffered from migraine without aura
since the age of 20 years. The characteristics of her migraine headache
were bilateral, pulsatile, and moderate to severe in intensity with
accompanying symptoms (photophobia, phonophobia, and osmopho-
bia) but without nausea. The patient reported a favorable response to
triptan; however, when left untreated, the migraine headaches lasted
for more than 4 hours. The recent headache frequency was 6 days/
month. On the initial examination, the patient weighed 53.0 kg and
was 152.0 cm tall with a body mass index of 22.9 kg/m2. There was
no cutaneous lesion in the trunk or extremities. No edema or varicose
vein in the legs was observed. Neurological examinations were
unremarkable except for bilateral absence of Achilles tendon reflex.
The ESS score was 15, and the PSQI global score was 13, indicating
excessive daytime sleepiness and decreased quality of sleep. She scored
20 on the BDI-II. The patient fulfilled the four essential diagnostic
Table 1. The Patient’s Clinical Course Following Immediate-release Pramipexole Treatment
Follow-up (month) Initial visit1 0 1 2 3 4 5
IRLS score 34 10 17 21 26 18
Migraine frequency (/month) 6 6 4 3 0 1
IRLS, International Restless Legs Syndrome Study Group Rating Scale.
1Immediate-release pramipexole treatment was initiated at 0.125 mg/day.
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4 53 21 27 16 Pulsating and
pressing
– .15/.15 0.375/30 5 5 4 Clonazepam 1 mg/day,
etizolam 0.5 mg/day,
betahistine mesilate 6 mg/
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30 mg/day
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71 57 22 56 30 Tightening + 3–4/1 0.125/23 20 14 13 Loxoprofen 60 mg/as
needed, atorvastatin 10 mg/
day, mecobalamin 1500 mg/
day, amlodipine 2.5 mg/day




91 20 29 20 13 Pulsating and
tightening
+ 15./3–4 0.125/2 40 14 20 Zolmitriptan 2.5 mg/as
needed, loxoprofen
60 mg/as needed,
betahistine mesilate 6 mg/
as needed, amitriptyline
10 mg/day, clonazepam










ESS, Epworth Sleepiness Scale; BDI-II, Beck Depression Inventory-II; IRLS, International Restless Legs Syndrome Study Group Rating Scale; PSQI, Pittsburgh Sleep Quality Index; RLS, Restless legs syndrome; P-IR,
immediate-release pramipexole.
1Pramipexole treatment began after the survey was performed between June and November 2010 from which the scores of BDI-II, PSQI and ESS of each patient was obtained.4






























































criteria of RLS:9 urge to move, worse at rest and evening, and
improvement with movement. The patient’s RLS symptoms were very
severe according to the IRLS (34/40). The laboratory data were
normal for liver, kidney, thyroid function, and blood count but showed
decreased serum iron levels (30 mg/dl) with normal ferritin levels
(62 ng/ml). RLS was diagnosed, and a low dose of P-IR treatment
(0.125 mg, 2 hours before bedtime) was started. Her RLS symptoms
markedly improved within a few days, and the IRLS score obtained on
the fourth day after treatment was decreased to 19. Five months later,
the patient was treated with an oral iron supplement for 2 months,
based on the laboratory findings of decreased ferritin levels of 33 ng/
ml (,50 ng/ml), and then instructed to eat iron-rich foods. Table 1
illustrates the patient’s clinical course following the P-IR treatment,
which reveals that P-IR treatment improved not only the IRLS score
but also headache frequency as reported by the patient.
Results
All patients were female, with a mean age of 35.3¡14.0 years. Nine
patients suffered from migraine without aura, while one (No. 5) had
migraine with aura. Except for two patients (Nos. 1 and 9), the onset of
migraine preceded the onset of RLS. P-IR treatment was markedly
effective for the RLS symptoms in all of the subjects. The characteristics
of the migraine patients with RLS who received chronic P-IR treatment
are shown in Table 2. Five out of 10 patients (Nos. 6–10; 50%) reported
significant improvements in migraine headache frequency and severity
following P-IR treatment. Four of these patients (80%) had reported
morning headaches before P-IR treatment in their headache diaries.
One patient (No. 6) reported that pulsating headache spontaneously
resolved without acute medication following P-IR treatment. No patient
reported worsening of headache or any changes in their mood, appetite,
or sleep habits after P-IR administration.
Discussion
In our study, our patient’s RLS symptoms and migraine headaches
exhibited favorable response to P-IR treatment, which is to our
knowledge the first clinical observation to support estimated
dopaminergic dysfunctions in both RLS and migraine. Combining
the review results of our previous study with the present case, 50% of
the patients who exhibited both migraines and RLS reported an
improvement in their headaches following low-dose P-IR treatment.
Our results indicated that the identification of RLS symptoms in
migraine patients is clinically significant; we found that when
migraines and RLS coexisted, dopaminergic treatment improved both
migraine and RLS symptoms in some patients. In five patients whose
RLS symptoms responded to P-IR, its effect on migraines was modest
compared with the marked effect of P-IR on RLS. In addition,
morning headache was frequently observed in these patients (Table 2,
No. 7–10; four of five [80%]), suggesting that P-IR may have beneficial
effects on migraine attack during sleep. In contrast to our study, which
showed improvement in headache in P-IR-treated patients, previous
randomized, double-blind, placebo-controlled studies of RLS patients
showed that headache occurred in approximately 13–15% of the RLS
patients who had received pramipexole treatment and in approxi-
mately 10–13% of those who had received placebo treatment.14,15
The involvement of dopamine in migraines is thought to be
complicated. The administration of low-dose dopamine agonists has
been shown to trigger attacks of premonitory symptoms such as
nausea, yawning, and food cravings in patients with migraine, and
dopamine antagonists have been reported to relieve these symptoms.6
Administration of D2-like receptor antagonists has been shown to be
effective for acute migraine attacks.16 In contrast, animal studies
suggest that dopamine agonists have a role in the headache phase of
migraines because the administration of D2-like dopamine receptor
agonists inhibits firing in the trigeminocervical complex.7 A significant
link between RLS and migraine has been suggested; however, the
reported opposing effects of dopaminergic agonists and antagonists in
the two diseases cannot be interpreted by a simplistic explanation at
the level of neurotransmitter release or receptor sensitivity.6 Thus, the
mechanism by which pramipexole improves migraine headaches
remains unclear. Specifically, it is unclear whether pramipexole
directly alleviates migraine headaches by improving central dopami-
nergic dysfunction or whether it improves compromised sleep quality
due to RLS and/or migraine. The latter possibility may be supported
by findings that among patients whose migraine headaches responded
to P-IR (Table 2, No. 6–10), the PSQI score was higher in patients
with morning headaches (No. 7–10) than in patients without morning
headaches (No. 6). Limitations of our study included the small number
of subjects studied and the lack of detailed examinations before and
after the administration of P-IR. In addition, improvement of migraine
following P-IR treatment might have been related to other
concomitant medications. Although our study did not include a
placebo group, the patients were advised of the possible effect only for
RLS and not for migraine. Nevertheless, placebo effects should still be
considered when treating patients with migraine, as emphasized in the
recent review paper.17 Different percentages of placebo effect are
shown in two conditions: 24–30% for acute treatment and 14–50% for
prophylactic treatment of headache. In this regard, because our study
evaluated both the acute and the prophylactic effect of pramipexole on
migraine headache, placebo effects may have arisen from the acute or
prophylactic nature of pramipexole, depending on the patients.
However, improvement in migraine headache was observed following
P-IR treatment in patients who had had morning headache before P-
IR treatment, suggesting that P-IR acts as an acute treatment for
migraine. In contrast, the observation that P-IR had no effects on
migraine headache in patients who had not had morning headache
before P-IR treatment may have resulted from insufficient duration of
action of P-IR. An extended-release formulation of pramipexole (P-
ER) may provide more stable dopaminergic stimulation than P-IR.
Whether P-ER is more effective than P-IR in ameliorating daytime
headaches in patients who do not have morning headaches requires
further studies. We did not perform questionnaires regarding insomnia
or sleepiness (PSQI or ESS) after P-IR treatment, and we could not
evaluate whether sleep status improved following P-IR treatment.
Further clinical studies are warranted to verify our results and to
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elucidate the mechanistic role of the dopaminergic system in both
migraines and RLS.
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